Arcutis Biotherapeutics, Inc. (ARQT) Financial Statements (2025 and earlier)

Company Profile

Business Address 3027 TOWNSGATE ROAD
WESTLAKE VILLAGE, CA 91361
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments227,955271,858409,589387,059284,441
Cash and cash equivalent71,33588,39553,64196,44965,082
Short-term investments156,620183,463355,948290,610219,359
Receivables73,06625,8078,458  
Inventory, net of allowances, customer advances and progress billings14,52613,1347,514  
Inventory14,52613,1347,514  
Prepaid expense9,0439,0727,2138,1811,468
Other undisclosed current assets11,23010,5604,6327,5336,917
Total current assets:335,820330,431437,406402,773292,826
Noncurrent Assets
Operating lease, right-of-use asset1,9532,3612,7213,0403,349
Property, plant and equipment1,0411,5391,8812,2612,016
Intangible assets, net (including goodwill)9,4796,4387,188  
Intangible assets, net (excluding goodwill)9,4796,4387,188  
Other noncurrent assets596596787878
Total noncurrent assets:13,06910,93411,8685,3795,443
TOTAL ASSETS:348,889341,365449,274408,152298,269
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities80,19345,93337,15032,89322,602
Accounts payable14,22011,9928,8277,3537,140
Accrued liabilities65,97333,94128,32325,54015,462
Other undisclosed current liabilities820735657433 
Total current liabilities:81,01346,66837,80733,32622,602
Noncurrent Liabilities
Long-term debt and lease obligation107,203201,799197,76977,1244,964
Long-term debt, excluding current maturities107,203201,799197,76972,350 
Liabilities, other than long-term debt3,1324,2314,1172582
Other liabilities570849 2582
Operating lease, liability2,5623,3824,1174,7744,964
Total noncurrent liabilities:110,335206,030201,88677,1495,046
Total liabilities:191,348252,698239,693110,47527,648
Equity
Equity, attributable to parent157,54188,667209,581297,677270,621
Common stock129654
Additional paid in capital1,279,4791,070,558930,425706,233472,569
Accumulated other comprehensive income (loss)(7)4(1,086)(255)(2)
Accumulated deficit(1,121,943)(981,904)(719,764)(408,306)(201,950)
Total equity:157,54188,667209,581297,677270,621
TOTAL LIABILITIES AND EQUITY:348,889341,365449,274408,152298,269

Income Statement (P&L) ($ in thousands)

3/31/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenues196,54259,6063,686  
Cost of revenue
(Cost of Product and Service Sold)
(19,128)(4,987)   
Gross profit:177,41454,6193,686  
Operating expenses(305,811)(295,720)(305,313)(206,529)(136,645)
Operating loss:(128,397)(241,101)(301,627)(206,529)(136,645)
Nonoperating income (expense)16,17311,786(9,831)173967
Other nonoperating income16,17311,7865,821  
Interest and debt expense(27,168)(29,712)(15,652)  
Loss from continuing operations before income taxes:(139,392)(259,027)(327,110)(206,356)(135,678)
Income tax expense(647)(3,113)   
Loss from continuing operations:(140,039)(262,140)(327,110)(206,356)(135,678)
Loss before gain (loss) on sale of properties:(206,356)(135,678)
Net loss:(140,039)(262,140)(327,110)(206,356)(135,678)
Other undisclosed net income attributable to parent   15,652  
Net loss available to common stockholders, diluted:(140,039)(262,140)(311,458)(206,356)(135,678)

Comprehensive Income ($ in thousands)

3/31/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net loss:(140,039)(262,140)(327,110)(206,356)(135,678)
Comprehensive loss:(140,039)(262,140)(327,110)(206,356)(135,678)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(11)1,09014,821(253)(1)
Comprehensive loss, net of tax, attributable to parent:(140,050)(261,050)(312,289)(206,609)(135,679)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: